Skip to main content
Clinical Trials/NCT05987761
NCT05987761
Recruiting
Not Applicable

Pivotal Response Treatment for Adolescents With High Functioning Autism Intervention Study

Stanford University1 site in 1 country76 target enrollmentSeptember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autism
Sponsor
Stanford University
Enrollment
76
Locations
1
Primary Endpoint
(Target) Change from baseline (Pre-training) in brain connectivity between superior temporal sulcus (STS) and the nucleus accumbens (NAc)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to identify improvement in behavioral and social function and changes in the brain following Pivotal Response Treatment (PRT) for Adolescents in highly verbal adolescents with autism spectrum disorder (ASD).

Registry
clinicaltrials.gov
Start Date
September 1, 2023
End Date
August 31, 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Daniel Abrams

Clinical Assistant Professor

Stanford University

Eligibility Criteria

Inclusion Criteria

  • Clinical Diagnosis of Autism Spectrum Disorder, higher functioning/low support needs
  • Intelligence Quotient (IQ): Participants with a Full Scale IQ \> 80 on the Wechsler Abbreviated Scale of Intelligence (WASI-II)
  • Right-handed
  • No metal in their body/unremovable metal on their body (i.e., braces)
  • First language is English
  • Must live in the San Francisco Bay Area
  • Able and willing to receive intervention weekly for 9 weeks
  • Adolescent is interested in improving their social skills
  • MRI Compatibility: No major contraindication for MRI.
  • Diagnosis of ASD using ADOS-2 and ADI-R.

Exclusion Criteria

  • History of claustrophobia, previous head injury, serious neurological or medical illness, birth weight less than 4 lb. and/or gestational age \< 34 weeks
  • Left-handed
  • Braces or any metal in their body

Outcomes

Primary Outcomes

(Target) Change from baseline (Pre-training) in brain connectivity between superior temporal sulcus (STS) and the nucleus accumbens (NAc)

Time Frame: Pre-treatment baseline, and between 11 to 13 weeks post-baseline

Target engagement consists of brain connectivity between voice selective superior temporal sulcus (STS) and the nucleus accumbens (NAc) of the mesolimbic reward system. For the PRT (i.e., intervention) group, brain connectivity will be measured using the generalized psychophysiological interaction (gPPI) model, a common measure of task-based brain connectivity using fMRI data. gPPI betas from individual subject contrast maps will be computed using the STS as a seed region and the NAc as the connectivity target region. Effect size will be computed using Cohen's d for a paired t-test comparing Post-Training and Pre-Training pSTS-NAc connectivity values (i.e., contrast betas): d = t/(sqrt(n) where t is the paired t-test and n the group size.

Change from baseline (Pre-training) in structured laboratory observations (SLO) of child-assessor interactions

Time Frame: Pre-treatment baseline, and between 11 to 13 weeks post-baseline

The Structured Laboratory Observations (SLO) of child-assessor interactions is a common behavioral measure of each participant's social communicative interactions assessed in a laboratory setting. The metric used to characterize the SLO is an overall percentage of appropriate social responsiveness. Change in baseline SLO will be computed by subtracting Post- from Pre-training percentage of appropriate social responsiveness for each participant in the PRT group.

Secondary Outcomes

  • (Secondary target) Change in brain connectivity between superior temporal sulcus (STS) and temporoparietal junction (TPJ)(Pre-treatment baseline, and between 11 to 13 weeks post-baseline)
  • Association between change in target engagement and change in clinical benefit (STS and NAc)(Pre-treatment baseline, and between 11 to 13 weeks post-baseline)
  • Group differences in the association between change in target engagement and clinical benefit (STS and NAc)(Pre-treatment baseline, and between 11 to 13 weeks post-baseline)
  • Group differences in the association between change in target engagement and clinical benefit (STS and TPJ)(Pre-treatment baseline, and between 11 to 13 weeks post-baseline)
  • Change in the Social Communication subscale of the Brief Observation of Social Communication Change (BOSCC)(Pre-treatment baseline, and between 11 to 13 weeks post-baseline)
  • Association between change in target engagement and change in clinical benefit (STS and TPJ)(Pre-treatment baseline, and between 11 to 13 weeks post-baseline)

Study Sites (1)

Loading locations...

Similar Trials